Trimipramine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:
|drugClass=Tricyclic antidepressant
|drugClass=Tricyclic antidepressant
|indication=depression
|indication=depression
|hasBlackBoxWarning=Yes
|adverseReactions=hypotension, tachycardia, constipation, xerostomia, dizziness, somnolence, blurred vision
|adverseReactions=hypotension, tachycardia, constipation, xerostomia, dizziness, somnolence, blurred vision
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
Line 102: Line 103:
* (Drug 3)
* (Drug 3)
:* (Description)
:* (Description)
|fdaPatientInfo=For patient information about Trimipramine from NLM, click [[Trimipramine (patient information)
|alcohol=Alcohol-Trimipramine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
|alcohol=Alcohol-Trimipramine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
}}
}}

Revision as of 13:46, 21 May 2014

{{DrugProjectFormSinglePage |authorTag=Pratik Bahekar, MBBS [1] |genericName=Trimipramine |aOrAn=a |drugClass=Tricyclic antidepressant |indication=depression |hasBlackBoxWarning=Yes |adverseReactions=hypotension, tachycardia, constipation, xerostomia, dizziness, somnolence, blurred vision |blackBoxWarningTitle=TITLE |blackBoxWarningBody=Condition Name: (Content)

|fdaLIADAdult=

Depression

  • 75 mg PO (divided into 1-3 doses per day), increase gradually to 150 mg/day to maximum 200 mg/day for outpatient treatment. Maintenance 50-150 mg/day PO, bedtime, for 3 months.
  • 100 mg PO (divided into 1-3 doses per day), increase gradually to 200 mg/day, if unsatisfactory response in in 2-3 weeks, increase to a maximum 300 mg/day for inpatient treatment.

|offLabelAdultGuideSupport=Condition 1

  • Developed by: (Organization)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

|offLabelAdultNoGuideSupport=:* There is limited information about Off-Label Non–Guideline-Supported Use of Trimipramine in adult patients.

|fdaLIADPed=

Depression

  • FDA approved for adolescents, and not for children.
  • 50 mg/day PO may increase up to 100 mg/day for adolescents;

|offLabelPedGuideSupport=Condition 1

  • Developed by: (Organization)
  • Class of Recommendation: (Class) (Link)
  • Strength of Evidence: (Category A/B/C) (Link)
  • Dosing Information/Recommendation
  • (Dosage)

|offLabelPedNoGuideSupport=:* There is limited information about Off-Label Non–Guideline-Supported Use of Trimipramine in pediatric patients. |contraindications=* Condition 1

  • Condition 2
  • Condition 3
  • Condition 4
  • Condition 5

|warnings=Conidition 1

(Description) |clinicalTrials=Central Nervous System

(list/description of adverse reactions)

Cardiovascular

(list/description of adverse reactions)

Respiratory

(list/description of adverse reactions)

Gastrointestinal

(list/description of adverse reactions)

Hypersensitive Reactions

(list/description of adverse reactions)

Miscellaneous

(list/description of adverse reactions)

|postmarketing=Central Nervous System

(list/description of adverse reactions)

Cardiovascular

(list/description of adverse reactions)

Respiratory

(list/description of adverse reactions)

Gastrointestinal

(list/description of adverse reactions)

Hypersensitive Reactions

(list/description of adverse reactions)

Miscellaneous

(list/description of adverse reactions)

|drugInteractions=* (Drug 1)

  • (Description)
  • (Drug 2)
  • (Description)
  • (Drug 3)
  • (Description)

|fdaPatientInfo=For patient information about Trimipramine from NLM, click [[Trimipramine (patient information) |alcohol=Alcohol-Trimipramine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication. }}